1. Home
  2. ATNM vs PTLE Comparison

ATNM vs PTLE Comparison

Compare ATNM & PTLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

SELL

Current Price

$0.97

Market Cap

37.1M

Sector

Health Care

ML Signal

SELL

PTLE

PTL LTD Ordinary Shares

N/A

Current Price

$7.35

Market Cap

44.0M

Sector

Energy

ML Signal

N/A

Company Overview

Basic Information
Metric
ATNM
PTLE
Founded
2000
2013
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oil Refining/Marketing
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
37.1M
44.0M
IPO Year
2013
2024

Fundamental Metrics

Financial Performance
Metric
ATNM
PTLE
Price
$0.97
$7.35
Analyst Decision
Buy
Analyst Count
4
0
Target Price
★ $3.60
N/A
AVG Volume (30 Days)
★ 98.9K
22.6K
Earning Date
11-13-2026
11-15-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 14.17
N/A
EPS
★ 0.71
N/A
Revenue
★ $90,000.00
N/A
Revenue This Year
$19,344.45
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.41
★ N/A
Revenue Growth
★ 11.11
N/A
52 Week Low
$0.74
$0.09
52 Week High
$1.74
$16.17

Technical Indicators

Market Signals
Indicator
ATNM
PTLE
Relative Strength Index (RSI) 34.56 53.64
Support Level $0.88 $6.61
Resistance Level $1.13 $7.86
Average True Range (ATR) 0.07 0.52
MACD -0.03 0.08
Stochastic Oscillator 1.27 80.88

Price Performance

Historical Comparison
ATNM
PTLE

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

About PTLE PTL LTD Ordinary Shares

PTL Ltd is a holding company. Through its subsidiaries, it is an established bunkering facilitator providing marine fuel logistics services for vessel refuelling, serving the Asia Pacific market. The company's services mainly involve facilitating with its suppliers to supply fuel for the use by the customers' vessels at various ports along their voyages in the Asia Pacific region; arranging vessel refuelling activities at competitive pricing to the customers; offering trade credit to the customers for vessel refuelling; handling unforeseeable circumstances faced by the customers and providing contingency solutions to the customers on time; and handling disputes, mainly concerning quality and quantity issues on marine fuel. The company derives its maximum revenue from Hong Kong.

Share on Social Networks: